in a Pandemic
2020 Virtual Nanomedicine Symposium
Thank you to all the participants, look for our next Symposium coming next fall.
With over 800 attendees, 300 questions asked and answered, and 13 speakers, you made PNI's first Virtual Nanomedicine Symposium a great success!
We will be sending out links to the sessions in the first week of August for those who attended the symposium and would like links to the recorded sessions.
If you could not attend the and would like to learn more about nanomedicine and view the recordings from the symposium, please fill out the form below, and we will be in touch with you.
The purpose of the RNA Symposium was to explore the necessary foundation to rapidly commercialize a COVID-19 vaccine and lay the groundwork
to revolutionize future epidemic response. This area of research significantly expands the known boundaries of the human genome and offers scientists and clinicians new avenues to understand the causes and treatment of disease.
July 23, 2020
Session 1: RNA Treatments and Vaccines for Infectious Disease Response
The Current Landscape
Introductory Information on RNA
Platform Technologies and Future Pandemic Preparedness
The Target Product Profile for RNA Vaccines
Session 2: RNA and Delivery Platform Technologies (Choose one from four breakout sessions)
Breakout A: Basics of RNA and RNA vaccines—
Sourcing enzymes IVT
Breakout B: Intro to RNA Delivery Technologies
Breakout C: Antigen Design Strategies
Breakout D: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Session 3: RNA Vaccine Demonstration:
Recreating formulations used in proof-of-concept studies in 2012 (Geall et al.) which was the first PoC demonstration of RNA-LNP vaccine, this time, using the NanoAssemblr® Platform, including the GMP System
Session 4: Manufacturing Platform Technology—Panel Discussion
Evolution of Various Approaches to Lipid Nanoparticle Production
Panel Discussion: How PNI Can Take Care of Lipids and LNPs for GMP Manufacturing
Concluding remarks: Implications of COVID-19 for RNA Medicines for Other Indications
Featured Speakers (confirmed)
Dr. Luis Brito, Moderna, Inc.
Dr. Yvonne Perrie, University of Strathclyde
Dr. Anton McCaffrey, TriLink
Dr. G Brett Robb, New England Biolabs
Annie Dosey, University of Washington
Dr. Lloyd Jeffs, Precision Nanosystems
Dr. Guarav Sahay, Oregon State University
Dr. Frank Slack, Harvard Medical School
Jessica Madigan, Trilink
Dr. Bijoyita Roy, New England Biolabs
Dr. Andy Geall Precision Nanosystems
Dr. Suraj Abraham, Precision Nanosystems
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.